OS Therapies announced it has aligned with key regulators including the FDA, MHRA, EMA, and TGA on the design of its Phase 3 trial for OST-HER2, a gene-edited cancer immunotherapy targeting osteosarcoma. The trial is set to begin in Australia in late Q3 2026, aiming to prevent or delay recurrence of pulmonary metastatic osteosarcoma. This alignment supports accelerated approval pathways in the U.S., U.K., Europe, and Australia, with potential regulatory decisions expected by year-end 2026 and patient access in 2027. OST-HER2 has received multiple designations such as Orphan Drug and Fast Track, enhancing its development and market access prospects.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
